Evonik (EVK GY) FY (EUR) Sales 14.1bln (exp. 14bln), Adj. EBITDA 1.87bln (exp. 1.87bln). FY Outlook: Adj. EBITDA 1.7-2bln (exp. 1.84bln)

Evonik (EVK GY) FY (EUR) Sales 14.1bln (exp. 14bln), Adj. EBITDA 1.87bln (exp. 1.87bln). FY Outlook: Adj. EBITDA 1.7-2bln (exp. 1.84bln)

Evonik's FY sales slightly beat expectations, which may indicate solid underlying demand. However, the FY outlook for adjusted EBITDA falls short of consensus, suggesting potential headwinds that could impact future profitability. This mixed performance might signal caution among investors, as the decreased guidance contrasts with their current results.